Canada Pension Plan Investment Board Sells 190,816 Shares of Amgen Inc. (NASDAQ:AMGN)

Canada Pension Plan Investment Board decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 22.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 662,190 shares of the medical research company's stock after selling 190,816 shares during the quarter. Canada Pension Plan Investment Board owned about 0.12% of Amgen worth $172,593,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Centricity Wealth Management LLC bought a new position in shares of Amgen during the 4th quarter worth about $25,000. Ritter Daniher Financial Advisory LLC DE boosted its stake in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new stake in Amgen in the 4th quarter valued at $34,000. Atala Financial Inc acquired a new position in shares of Amgen in the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC bought a new stake in Amgen in the fourth quarter valued at about $36,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company's stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 over the last ninety days. Insiders own 0.69% of the company's stock.

Amgen Stock Performance

AMGN stock traded up $0.26 during trading hours on Wednesday, reaching $278.66. The stock had a trading volume of 691,480 shares, compared to its average volume of 2,781,306. The stock has a market capitalization of $149.82 billion, a PE ratio of 36.91, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The stock has a 50-day simple moving average of $302.25 and a 200 day simple moving average of $293.45. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.42%. Amgen's dividend payout ratio (DPR) is 126.09%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. Wells Fargo & Company reiterated an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Johnson Rice set a $294.00 target price on shares of Amgen in a research note on Wednesday, March 5th. Piper Sandler raised their price target on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Bank of America increased their target price on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Finally, Citigroup restated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $310.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.